nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—migraine—Prednisone—hematologic cancer	0.209	0.508	CpDpCtD
Cyclobenzaprine—osteoarthritis—Prednisone—hematologic cancer	0.203	0.492	CpDpCtD
Cyclobenzaprine—CYP1A2—Anagrelide—hematologic cancer	0.0338	0.0847	CbGbCtD
Cyclobenzaprine—CYP2D6—Lomustine—hematologic cancer	0.018	0.045	CbGbCtD
Cyclobenzaprine—CYP1A2—Carmustine—hematologic cancer	0.0178	0.0445	CbGbCtD
Cyclobenzaprine—CYP2D6—Idarubicin—hematologic cancer	0.016	0.0401	CbGbCtD
Cyclobenzaprine—CYP1A2—Methoxsalen—hematologic cancer	0.0151	0.0378	CbGbCtD
Cyclobenzaprine—CYP1A2—Bortezomib—hematologic cancer	0.0144	0.036	CbGbCtD
Cyclobenzaprine—CYP1A2—Daunorubicin—hematologic cancer	0.0137	0.0344	CbGbCtD
Cyclobenzaprine—CYP2D6—Hydroxyurea—hematologic cancer	0.0136	0.0341	CbGbCtD
Cyclobenzaprine—CYP1A2—Alitretinoin—hematologic cancer	0.0135	0.0337	CbGbCtD
Cyclobenzaprine—CYP1A2—Thalidomide—hematologic cancer	0.0125	0.0314	CbGbCtD
Cyclobenzaprine—CYP3A4—Bexarotene—hematologic cancer	0.0123	0.0308	CbGbCtD
Cyclobenzaprine—CYP2D6—Bortezomib—hematologic cancer	0.0118	0.0297	CbGbCtD
Cyclobenzaprine—CYP3A4—Lomustine—hematologic cancer	0.0114	0.0286	CbGbCtD
Cyclobenzaprine—CYP3A4—Busulfan—hematologic cancer	0.0114	0.0286	CbGbCtD
Cyclobenzaprine—CYP1A2—Dacarbazine—hematologic cancer	0.0108	0.027	CbGbCtD
Cyclobenzaprine—CYP1A2—Imatinib—hematologic cancer	0.0105	0.0264	CbGbCtD
Cyclobenzaprine—CYP3A4—Thiotepa—hematologic cancer	0.0102	0.0255	CbGbCtD
Cyclobenzaprine—CYP2D6—Imatinib—hematologic cancer	0.00867	0.0217	CbGbCtD
Cyclobenzaprine—CYP1A2—Dasatinib—hematologic cancer	0.00845	0.0212	CbGbCtD
Cyclobenzaprine—CYP3A4—Methoxsalen—hematologic cancer	0.00791	0.0198	CbGbCtD
Cyclobenzaprine—CYP2D6—Nilotinib—hematologic cancer	0.00788	0.0197	CbGbCtD
Cyclobenzaprine—CYP2D6—Vinorelbine—hematologic cancer	0.00781	0.0196	CbGbCtD
Cyclobenzaprine—CYP3A4—Bortezomib—hematologic cancer	0.00753	0.0189	CbGbCtD
Cyclobenzaprine—CYP3A4—Daunorubicin—hematologic cancer	0.0072	0.018	CbGbCtD
Cyclobenzaprine—CYP3A4—Cytarabine—hematologic cancer	0.00635	0.0159	CbGbCtD
Cyclobenzaprine—CYP3A4—Teniposide—hematologic cancer	0.00625	0.0157	CbGbCtD
Cyclobenzaprine—CYP3A4—Ifosfamide—hematologic cancer	0.00577	0.0145	CbGbCtD
Cyclobenzaprine—CYP3A4—Imatinib—hematologic cancer	0.00551	0.0138	CbGbCtD
Cyclobenzaprine—CYP1A2—Etoposide—hematologic cancer	0.00526	0.0132	CbGbCtD
Cyclobenzaprine—CYP3A4—Ruxolitinib—hematologic cancer	0.00519	0.013	CbGbCtD
Cyclobenzaprine—CYP3A4—Nilotinib—hematologic cancer	0.00501	0.0126	CbGbCtD
Cyclobenzaprine—CYP3A4—Vinorelbine—hematologic cancer	0.00497	0.0125	CbGbCtD
Cyclobenzaprine—CYP2D6—Vinblastine—hematologic cancer	0.00482	0.0121	CbGbCtD
Cyclobenzaprine—CYP3A4—Triamcinolone—hematologic cancer	0.00454	0.0114	CbGbCtD
Cyclobenzaprine—CYP3A4—Dasatinib—hematologic cancer	0.00443	0.0111	CbGbCtD
Cyclobenzaprine—CYP3A4—Mitoxantrone—hematologic cancer	0.00437	0.011	CbGbCtD
Cyclobenzaprine—CYP3A4—Betamethasone—hematologic cancer	0.0039	0.00977	CbGbCtD
Cyclobenzaprine—CYP3A4—Prednisolone—hematologic cancer	0.00385	0.00964	CbGbCtD
Cyclobenzaprine—CYP3A4—Prednisone—hematologic cancer	0.00363	0.0091	CbGbCtD
Cyclobenzaprine—CYP2D6—Dexamethasone—hematologic cancer	0.00357	0.00894	CbGbCtD
Cyclobenzaprine—CYP3A4—Irinotecan—hematologic cancer	0.00344	0.00863	CbGbCtD
Cyclobenzaprine—CYP3A4—Vinblastine—hematologic cancer	0.00306	0.00767	CbGbCtD
Cyclobenzaprine—CYP3A4—Vincristine—hematologic cancer	0.00301	0.00754	CbGbCtD
Cyclobenzaprine—CYP2D6—Doxorubicin—hematologic cancer	0.00296	0.00742	CbGbCtD
Cyclobenzaprine—CYP3A4—Etoposide—hematologic cancer	0.00276	0.00691	CbGbCtD
Cyclobenzaprine—CYP3A4—Dexamethasone—hematologic cancer	0.00227	0.00568	CbGbCtD
Cyclobenzaprine—CYP3A4—Doxorubicin—hematologic cancer	0.00188	0.00472	CbGbCtD
Cyclobenzaprine—Diphenhydramine—SLC22A1—hematologic cancer	7e-05	0.148	CrCbGaD
Cyclobenzaprine—Protriptyline—ABCB1—hematologic cancer	5.75e-05	0.121	CrCbGaD
Cyclobenzaprine—Imipramine—SLC22A1—hematologic cancer	5.29e-05	0.112	CrCbGaD
Cyclobenzaprine—Tamoxifen—ABCG2—hematologic cancer	4.76e-05	0.1	CrCbGaD
Cyclobenzaprine—Tamoxifen—ESR1—hematologic cancer	4.67e-05	0.0985	CrCbGaD
Cyclobenzaprine—Carbamazepine—ABCB1—hematologic cancer	2.67e-05	0.0564	CrCbGaD
Cyclobenzaprine—Paraesthesia—Dexamethasone—hematologic cancer	2.54e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Betamethasone—hematologic cancer	2.54e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Discomfort—Prednisone—hematologic cancer	2.54e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Rash—Gemcitabine—hematologic cancer	2.54e-05	0.000147	CcSEcCtD
Cyclobenzaprine—Dermatitis—Gemcitabine—hematologic cancer	2.54e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Etoposide—hematologic cancer	2.54e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Tinnitus—Epirubicin—hematologic cancer	2.53e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Headache—Gemcitabine—hematologic cancer	2.52e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Nausea—Vincristine—hematologic cancer	2.52e-05	0.000146	CcSEcCtD
Cyclobenzaprine—Hepatitis—Doxorubicin—hematologic cancer	2.51e-05	0.000145	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Prednisolone—hematologic cancer	2.5e-05	0.000144	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Doxorubicin—hematologic cancer	2.5e-05	0.000144	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Doxorubicin—hematologic cancer	2.49e-05	0.000144	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Dexamethasone—hematologic cancer	2.49e-05	0.000144	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Betamethasone—hematologic cancer	2.49e-05	0.000144	CcSEcCtD
Cyclobenzaprine—Urticaria—Triamcinolone—hematologic cancer	2.48e-05	0.000143	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—hematologic cancer	2.47e-05	0.000143	CcSEcCtD
Cyclobenzaprine—Asthenia—Etoposide—hematologic cancer	2.47e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Prednisone—hematologic cancer	2.47e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Oedema—Prednisone—hematologic cancer	2.47e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Dexamethasone—hematologic cancer	2.46e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Betamethasone—hematologic cancer	2.46e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Nausea—Mitoxantrone—hematologic cancer	2.46e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Nausea—Irinotecan—hematologic cancer	2.46e-05	0.000142	CcSEcCtD
Cyclobenzaprine—Fatigue—Betamethasone—hematologic cancer	2.44e-05	0.000141	CcSEcCtD
Cyclobenzaprine—Fatigue—Dexamethasone—hematologic cancer	2.44e-05	0.000141	CcSEcCtD
Cyclobenzaprine—Pruritus—Etoposide—hematologic cancer	2.43e-05	0.00014	CcSEcCtD
Cyclobenzaprine—Shock—Prednisone—hematologic cancer	2.43e-05	0.00014	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Epirubicin—hematologic cancer	2.43e-05	0.00014	CcSEcCtD
Cyclobenzaprine—Tachycardia—Prednisone—hematologic cancer	2.41e-05	0.000139	CcSEcCtD
Cyclobenzaprine—Alopecia—Epirubicin—hematologic cancer	2.4e-05	0.000138	CcSEcCtD
Cyclobenzaprine—Nausea—Gemcitabine—hematologic cancer	2.39e-05	0.000138	CcSEcCtD
Cyclobenzaprine—Vomiting—Cisplatin—hematologic cancer	2.39e-05	0.000138	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Prednisone—hematologic cancer	2.38e-05	0.000138	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—hematologic cancer	2.38e-05	0.000137	CcSEcCtD
Cyclobenzaprine—Rash—Cisplatin—hematologic cancer	2.37e-05	0.000137	CcSEcCtD
Cyclobenzaprine—Dermatitis—Cisplatin—hematologic cancer	2.37e-05	0.000137	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Etoposide—hematologic cancer	2.35e-05	0.000136	CcSEcCtD
Cyclobenzaprine—Anorexia—Prednisone—hematologic cancer	2.35e-05	0.000136	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—hematologic cancer	2.34e-05	0.000135	CcSEcCtD
Cyclobenzaprine—Tinnitus—Doxorubicin—hematologic cancer	2.34e-05	0.000135	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Dexamethasone—hematologic cancer	2.33e-05	0.000135	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Betamethasone—hematologic cancer	2.33e-05	0.000135	CcSEcCtD
Cyclobenzaprine—Flatulence—Epirubicin—hematologic cancer	2.33e-05	0.000134	CcSEcCtD
Cyclobenzaprine—Tension—Epirubicin—hematologic cancer	2.32e-05	0.000134	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.32e-05	0.000134	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Betamethasone—hematologic cancer	2.32e-05	0.000134	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Epirubicin—hematologic cancer	2.31e-05	0.000134	CcSEcCtD
Cyclobenzaprine—Nortriptyline—ALB—hematologic cancer	2.31e-05	0.0487	CrCbGaD
Cyclobenzaprine—Hypersensitivity—Triamcinolone—hematologic cancer	2.3e-05	0.000133	CcSEcCtD
Cyclobenzaprine—Nervousness—Epirubicin—hematologic cancer	2.3e-05	0.000132	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—hematologic cancer	2.28e-05	0.000131	CcSEcCtD
Cyclobenzaprine—Dizziness—Etoposide—hematologic cancer	2.28e-05	0.000131	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—hematologic cancer	2.27e-05	0.000131	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—hematologic cancer	2.26e-05	0.00013	CcSEcCtD
Cyclobenzaprine—Urticaria—Dexamethasone—hematologic cancer	2.25e-05	0.00013	CcSEcCtD
Cyclobenzaprine—Urticaria—Betamethasone—hematologic cancer	2.25e-05	0.00013	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.25e-05	0.00013	CcSEcCtD
Cyclobenzaprine—Dizziness—Prednisolone—hematologic cancer	2.24e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Doxorubicin—hematologic cancer	2.24e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Chlorprothixene—ABCB1—hematologic cancer	2.24e-05	0.0473	CrCbGaD
Cyclobenzaprine—Asthenia—Triamcinolone—hematologic cancer	2.24e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Dexamethasone—hematologic cancer	2.24e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Betamethasone—hematologic cancer	2.24e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Nausea—Cisplatin—hematologic cancer	2.23e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Insomnia—Prednisone—hematologic cancer	2.23e-05	0.000129	CcSEcCtD
Cyclobenzaprine—Vision blurred—Epirubicin—hematologic cancer	2.23e-05	0.000128	CcSEcCtD
Cyclobenzaprine—Alopecia—Doxorubicin—hematologic cancer	2.22e-05	0.000128	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Prednisone—hematologic cancer	2.21e-05	0.000128	CcSEcCtD
Cyclobenzaprine—Pruritus—Triamcinolone—hematologic cancer	2.21e-05	0.000127	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Epirubicin—hematologic cancer	2.19e-05	0.000127	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—hematologic cancer	2.19e-05	0.000126	CcSEcCtD
Cyclobenzaprine—Vomiting—Etoposide—hematologic cancer	2.19e-05	0.000126	CcSEcCtD
Cyclobenzaprine—Agitation—Epirubicin—hematologic cancer	2.17e-05	0.000125	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Prednisone—hematologic cancer	2.17e-05	0.000125	CcSEcCtD
Cyclobenzaprine—Rash—Etoposide—hematologic cancer	2.17e-05	0.000125	CcSEcCtD
Cyclobenzaprine—Dermatitis—Etoposide—hematologic cancer	2.17e-05	0.000125	CcSEcCtD
Cyclobenzaprine—Headache—Etoposide—hematologic cancer	2.16e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Flatulence—Doxorubicin—hematologic cancer	2.16e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—hematologic cancer	2.15e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—hematologic cancer	2.15e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Tension—Doxorubicin—hematologic cancer	2.15e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Prednisone—hematologic cancer	2.14e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Doxorubicin—hematologic cancer	2.14e-05	0.000124	CcSEcCtD
Cyclobenzaprine—Rash—Prednisolone—hematologic cancer	2.14e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Dermatitis—Prednisolone—hematologic cancer	2.14e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Malaise—Epirubicin—hematologic cancer	2.13e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Fatigue—Prednisone—hematologic cancer	2.13e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Headache—Prednisolone—hematologic cancer	2.13e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—hematologic cancer	2.12e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Nervousness—Doxorubicin—hematologic cancer	2.12e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Vertigo—Epirubicin—hematologic cancer	2.12e-05	0.000123	CcSEcCtD
Cyclobenzaprine—Syncope—Epirubicin—hematologic cancer	2.12e-05	0.000122	CcSEcCtD
Cyclobenzaprine—Leukopenia—Epirubicin—hematologic cancer	2.12e-05	0.000122	CcSEcCtD
Cyclobenzaprine—Constipation—Prednisone—hematologic cancer	2.11e-05	0.000122	CcSEcCtD
Cyclobenzaprine—Palpitations—Epirubicin—hematologic cancer	2.09e-05	0.00012	CcSEcCtD
Cyclobenzaprine—Confusional state—Methotrexate—hematologic cancer	2.08e-05	0.00012	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Epirubicin—hematologic cancer	2.08e-05	0.00012	CcSEcCtD
Cyclobenzaprine—Trimipramine—ABCB1—hematologic cancer	2.07e-05	0.0437	CrCbGaD
Cyclobenzaprine—Dizziness—Triamcinolone—hematologic cancer	2.06e-05	0.000119	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—hematologic cancer	2.06e-05	0.000119	CcSEcCtD
Cyclobenzaprine—Vision blurred—Doxorubicin—hematologic cancer	2.06e-05	0.000119	CcSEcCtD
Cyclobenzaprine—Convulsion—Epirubicin—hematologic cancer	2.05e-05	0.000118	CcSEcCtD
Cyclobenzaprine—Nausea—Etoposide—hematologic cancer	2.04e-05	0.000118	CcSEcCtD
Cyclobenzaprine—Hypertension—Epirubicin—hematologic cancer	2.04e-05	0.000118	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Prednisone—hematologic cancer	2.03e-05	0.000117	CcSEcCtD
Cyclobenzaprine—Asthenia—Dexamethasone—hematologic cancer	2.03e-05	0.000117	CcSEcCtD
Cyclobenzaprine—Asthenia—Betamethasone—hematologic cancer	2.03e-05	0.000117	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Doxorubicin—hematologic cancer	2.03e-05	0.000117	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—hematologic cancer	2.02e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Prednisone—hematologic cancer	2.02e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Nausea—Prednisolone—hematologic cancer	2.02e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Chest pain—Epirubicin—hematologic cancer	2.01e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Myalgia—Epirubicin—hematologic cancer	2.01e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Agitation—Doxorubicin—hematologic cancer	2.01e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Anxiety—Epirubicin—hematologic cancer	2.01e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Pruritus—Betamethasone—hematologic cancer	2e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Pruritus—Dexamethasone—hematologic cancer	2e-05	0.000116	CcSEcCtD
Cyclobenzaprine—Promethazine—ABCB1—hematologic cancer	2e-05	0.0421	CrCbGaD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—hematologic cancer	1.99e-05	0.000115	CcSEcCtD
Cyclobenzaprine—Discomfort—Epirubicin—hematologic cancer	1.99e-05	0.000115	CcSEcCtD
Cyclobenzaprine—Vomiting—Triamcinolone—hematologic cancer	1.98e-05	0.000114	CcSEcCtD
Cyclobenzaprine—Tamoxifen—ABCB1—hematologic cancer	1.98e-05	0.0418	CrCbGaD
Cyclobenzaprine—Doxepin—ABCB1—hematologic cancer	1.98e-05	0.0417	CrCbGaD
Cyclobenzaprine—Malaise—Doxorubicin—hematologic cancer	1.97e-05	0.000114	CcSEcCtD
Cyclobenzaprine—Rash—Triamcinolone—hematologic cancer	1.97e-05	0.000114	CcSEcCtD
Cyclobenzaprine—Dry mouth—Epirubicin—hematologic cancer	1.97e-05	0.000114	CcSEcCtD
Cyclobenzaprine—Dermatitis—Triamcinolone—hematologic cancer	1.97e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Vertigo—Doxorubicin—hematologic cancer	1.96e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—hematologic cancer	1.96e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Syncope—Doxorubicin—hematologic cancer	1.96e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Urticaria—Prednisone—hematologic cancer	1.96e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Leukopenia—Doxorubicin—hematologic cancer	1.96e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Headache—Triamcinolone—hematologic cancer	1.96e-05	0.000113	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Prednisone—hematologic cancer	1.95e-05	0.000112	CcSEcCtD
Cyclobenzaprine—Confusional state—Epirubicin—hematologic cancer	1.95e-05	0.000112	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Dexamethasone—hematologic cancer	1.94e-05	0.000112	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Betamethasone—hematologic cancer	1.94e-05	0.000112	CcSEcCtD
Cyclobenzaprine—Palpitations—Doxorubicin—hematologic cancer	1.93e-05	0.000111	CcSEcCtD
Cyclobenzaprine—Oedema—Epirubicin—hematologic cancer	1.93e-05	0.000111	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Epirubicin—hematologic cancer	1.93e-05	0.000111	CcSEcCtD
Cyclobenzaprine—Hypotension—Methotrexate—hematologic cancer	1.93e-05	0.000111	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Doxorubicin—hematologic cancer	1.92e-05	0.000111	CcSEcCtD
Cyclobenzaprine—Shock—Epirubicin—hematologic cancer	1.9e-05	0.000109	CcSEcCtD
Cyclobenzaprine—Convulsion—Doxorubicin—hematologic cancer	1.89e-05	0.000109	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Epirubicin—hematologic cancer	1.89e-05	0.000109	CcSEcCtD
Cyclobenzaprine—Hypertension—Doxorubicin—hematologic cancer	1.89e-05	0.000109	CcSEcCtD
Cyclobenzaprine—Tachycardia—Epirubicin—hematologic cancer	1.88e-05	0.000109	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.88e-05	0.000108	CcSEcCtD
Cyclobenzaprine—Dizziness—Betamethasone—hematologic cancer	1.87e-05	0.000108	CcSEcCtD
Cyclobenzaprine—Dizziness—Dexamethasone—hematologic cancer	1.87e-05	0.000108	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Epirubicin—hematologic cancer	1.86e-05	0.000108	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—hematologic cancer	1.86e-05	0.000108	CcSEcCtD
Cyclobenzaprine—Chest pain—Doxorubicin—hematologic cancer	1.86e-05	0.000107	CcSEcCtD
Cyclobenzaprine—Myalgia—Doxorubicin—hematologic cancer	1.86e-05	0.000107	CcSEcCtD
Cyclobenzaprine—Anxiety—Doxorubicin—hematologic cancer	1.86e-05	0.000107	CcSEcCtD
Cyclobenzaprine—Nausea—Triamcinolone—hematologic cancer	1.85e-05	0.000107	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methotrexate—hematologic cancer	1.85e-05	0.000107	CcSEcCtD
Cyclobenzaprine—Discomfort—Doxorubicin—hematologic cancer	1.84e-05	0.000106	CcSEcCtD
Cyclobenzaprine—Anorexia—Epirubicin—hematologic cancer	1.84e-05	0.000106	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—hematologic cancer	1.84e-05	0.000106	CcSEcCtD
Cyclobenzaprine—Somnolence—Methotrexate—hematologic cancer	1.83e-05	0.000106	CcSEcCtD
Cyclobenzaprine—Dry mouth—Doxorubicin—hematologic cancer	1.82e-05	0.000105	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Prednisone—hematologic cancer	1.82e-05	0.000105	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methotrexate—hematologic cancer	1.81e-05	0.000105	CcSEcCtD
Cyclobenzaprine—Hypotension—Epirubicin—hematologic cancer	1.8e-05	0.000104	CcSEcCtD
Cyclobenzaprine—Vomiting—Dexamethasone—hematologic cancer	1.8e-05	0.000104	CcSEcCtD
Cyclobenzaprine—Vomiting—Betamethasone—hematologic cancer	1.8e-05	0.000104	CcSEcCtD
Cyclobenzaprine—Confusional state—Doxorubicin—hematologic cancer	1.8e-05	0.000104	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—hematologic cancer	1.79e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Rash—Betamethasone—hematologic cancer	1.79e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Rash—Dexamethasone—hematologic cancer	1.79e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Oedema—Doxorubicin—hematologic cancer	1.78e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Doxorubicin—hematologic cancer	1.78e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Dermatitis—Dexamethasone—hematologic cancer	1.78e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Dermatitis—Betamethasone—hematologic cancer	1.78e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—hematologic cancer	1.78e-05	0.000103	CcSEcCtD
Cyclobenzaprine—Headache—Betamethasone—hematologic cancer	1.77e-05	0.000102	CcSEcCtD
Cyclobenzaprine—Headache—Dexamethasone—hematologic cancer	1.77e-05	0.000102	CcSEcCtD
Cyclobenzaprine—Asthenia—Prednisone—hematologic cancer	1.77e-05	0.000102	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.76e-05	0.000101	CcSEcCtD
Cyclobenzaprine—Shock—Doxorubicin—hematologic cancer	1.76e-05	0.000101	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Doxorubicin—hematologic cancer	1.75e-05	0.000101	CcSEcCtD
Cyclobenzaprine—Pruritus—Prednisone—hematologic cancer	1.75e-05	0.000101	CcSEcCtD
Cyclobenzaprine—Insomnia—Epirubicin—hematologic cancer	1.74e-05	0.000101	CcSEcCtD
Cyclobenzaprine—Tachycardia—Doxorubicin—hematologic cancer	1.74e-05	0.0001	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Epirubicin—hematologic cancer	1.73e-05	9.99e-05	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Doxorubicin—hematologic cancer	1.73e-05	9.95e-05	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Epirubicin—hematologic cancer	1.72e-05	9.92e-05	CcSEcCtD
Cyclobenzaprine—Somnolence—Epirubicin—hematologic cancer	1.71e-05	9.89e-05	CcSEcCtD
Cyclobenzaprine—Anorexia—Doxorubicin—hematologic cancer	1.7e-05	9.81e-05	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methotrexate—hematologic cancer	1.7e-05	9.8e-05	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Epirubicin—hematologic cancer	1.7e-05	9.8e-05	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Prednisone—hematologic cancer	1.69e-05	9.73e-05	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.69e-05	9.72e-05	CcSEcCtD
Cyclobenzaprine—Nausea—Betamethasone—hematologic cancer	1.68e-05	9.7e-05	CcSEcCtD
Cyclobenzaprine—Nausea—Dexamethasone—hematologic cancer	1.68e-05	9.7e-05	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Epirubicin—hematologic cancer	1.68e-05	9.67e-05	CcSEcCtD
Cyclobenzaprine—Hypotension—Doxorubicin—hematologic cancer	1.67e-05	9.62e-05	CcSEcCtD
Cyclobenzaprine—Fatigue—Epirubicin—hematologic cancer	1.66e-05	9.59e-05	CcSEcCtD
Cyclobenzaprine—Constipation—Epirubicin—hematologic cancer	1.65e-05	9.52e-05	CcSEcCtD
Cyclobenzaprine—Urticaria—Methotrexate—hematologic cancer	1.64e-05	9.45e-05	CcSEcCtD
Cyclobenzaprine—Dizziness—Prednisone—hematologic cancer	1.63e-05	9.41e-05	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methotrexate—hematologic cancer	1.63e-05	9.4e-05	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.63e-05	9.38e-05	CcSEcCtD
Cyclobenzaprine—Insomnia—Doxorubicin—hematologic cancer	1.61e-05	9.31e-05	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Doxorubicin—hematologic cancer	1.6e-05	9.25e-05	CcSEcCtD
Cyclobenzaprine—Amitriptyline—ALB—hematologic cancer	1.6e-05	0.0338	CrCbGaD
Cyclobenzaprine—Dyspnoea—Doxorubicin—hematologic cancer	1.59e-05	9.18e-05	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Epirubicin—hematologic cancer	1.59e-05	9.17e-05	CcSEcCtD
Cyclobenzaprine—Somnolence—Doxorubicin—hematologic cancer	1.59e-05	9.15e-05	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.58e-05	9.1e-05	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Doxorubicin—hematologic cancer	1.57e-05	9.06e-05	CcSEcCtD
Cyclobenzaprine—Vomiting—Prednisone—hematologic cancer	1.57e-05	9.05e-05	CcSEcCtD
Cyclobenzaprine—Rash—Prednisone—hematologic cancer	1.56e-05	8.97e-05	CcSEcCtD
Cyclobenzaprine—Dermatitis—Prednisone—hematologic cancer	1.55e-05	8.96e-05	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Doxorubicin—hematologic cancer	1.55e-05	8.95e-05	CcSEcCtD
Cyclobenzaprine—Headache—Prednisone—hematologic cancer	1.55e-05	8.91e-05	CcSEcCtD
Cyclobenzaprine—Fatigue—Doxorubicin—hematologic cancer	1.54e-05	8.88e-05	CcSEcCtD
Cyclobenzaprine—Imipramine—ABCB1—hematologic cancer	1.54e-05	0.0324	CrCbGaD
Cyclobenzaprine—Urticaria—Epirubicin—hematologic cancer	1.53e-05	8.84e-05	CcSEcCtD
Cyclobenzaprine—Amitriptyline—ABCB1—hematologic cancer	1.53e-05	0.0322	CrCbGaD
Cyclobenzaprine—Constipation—Doxorubicin—hematologic cancer	1.53e-05	8.8e-05	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Epirubicin—hematologic cancer	1.52e-05	8.8e-05	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Methotrexate—hematologic cancer	1.52e-05	8.76e-05	CcSEcCtD
Cyclobenzaprine—Asthenia—Methotrexate—hematologic cancer	1.48e-05	8.53e-05	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Doxorubicin—hematologic cancer	1.47e-05	8.48e-05	CcSEcCtD
Cyclobenzaprine—Nausea—Prednisone—hematologic cancer	1.47e-05	8.45e-05	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.46e-05	8.42e-05	CcSEcCtD
Cyclobenzaprine—Pruritus—Methotrexate—hematologic cancer	1.46e-05	8.41e-05	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Epirubicin—hematologic cancer	1.42e-05	8.2e-05	CcSEcCtD
Cyclobenzaprine—Urticaria—Doxorubicin—hematologic cancer	1.42e-05	8.18e-05	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Doxorubicin—hematologic cancer	1.41e-05	8.14e-05	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methotrexate—hematologic cancer	1.41e-05	8.14e-05	CcSEcCtD
Cyclobenzaprine—Asthenia—Epirubicin—hematologic cancer	1.38e-05	7.98e-05	CcSEcCtD
Cyclobenzaprine—Pruritus—Epirubicin—hematologic cancer	1.36e-05	7.87e-05	CcSEcCtD
Cyclobenzaprine—Dizziness—Methotrexate—hematologic cancer	1.36e-05	7.86e-05	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Epirubicin—hematologic cancer	1.32e-05	7.61e-05	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Doxorubicin—hematologic cancer	1.32e-05	7.59e-05	CcSEcCtD
Cyclobenzaprine—Vomiting—Methotrexate—hematologic cancer	1.31e-05	7.56e-05	CcSEcCtD
Cyclobenzaprine—Rash—Methotrexate—hematologic cancer	1.3e-05	7.5e-05	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—hematologic cancer	1.3e-05	7.49e-05	CcSEcCtD
Cyclobenzaprine—Headache—Methotrexate—hematologic cancer	1.29e-05	7.45e-05	CcSEcCtD
Cyclobenzaprine—Asthenia—Doxorubicin—hematologic cancer	1.28e-05	7.39e-05	CcSEcCtD
Cyclobenzaprine—Dizziness—Epirubicin—hematologic cancer	1.28e-05	7.36e-05	CcSEcCtD
Cyclobenzaprine—Pruritus—Doxorubicin—hematologic cancer	1.26e-05	7.28e-05	CcSEcCtD
Cyclobenzaprine—Vomiting—Epirubicin—hematologic cancer	1.23e-05	7.08e-05	CcSEcCtD
Cyclobenzaprine—Nausea—Methotrexate—hematologic cancer	1.22e-05	7.06e-05	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Doxorubicin—hematologic cancer	1.22e-05	7.04e-05	CcSEcCtD
Cyclobenzaprine—Rash—Epirubicin—hematologic cancer	1.22e-05	7.02e-05	CcSEcCtD
Cyclobenzaprine—Dermatitis—Epirubicin—hematologic cancer	1.22e-05	7.01e-05	CcSEcCtD
Cyclobenzaprine—Headache—Epirubicin—hematologic cancer	1.21e-05	6.97e-05	CcSEcCtD
Cyclobenzaprine—Dizziness—Doxorubicin—hematologic cancer	1.18e-05	6.81e-05	CcSEcCtD
Cyclobenzaprine—Nausea—Epirubicin—hematologic cancer	1.15e-05	6.61e-05	CcSEcCtD
Cyclobenzaprine—Vomiting—Doxorubicin—hematologic cancer	1.13e-05	6.55e-05	CcSEcCtD
Cyclobenzaprine—Rash—Doxorubicin—hematologic cancer	1.13e-05	6.49e-05	CcSEcCtD
Cyclobenzaprine—Dermatitis—Doxorubicin—hematologic cancer	1.12e-05	6.49e-05	CcSEcCtD
Cyclobenzaprine—Headache—Doxorubicin—hematologic cancer	1.12e-05	6.45e-05	CcSEcCtD
Cyclobenzaprine—Nausea—Doxorubicin—hematologic cancer	1.06e-05	6.12e-05	CcSEcCtD
Cyclobenzaprine—HTR2A—Signaling Pathways—SDC1—hematologic cancer	5.12e-06	0.000336	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTHLH—hematologic cancer	5.12e-06	0.000336	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOR2—hematologic cancer	5.09e-06	0.000333	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL2RA—hematologic cancer	5.03e-06	0.00033	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—AGRN—hematologic cancer	5.03e-06	0.00033	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PC—hematologic cancer	5.03e-06	0.00033	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTGER4—hematologic cancer	4.98e-06	0.000327	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—LCK—hematologic cancer	4.96e-06	0.000325	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—H3F3A—hematologic cancer	4.86e-06	0.000319	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC35B2—hematologic cancer	4.86e-06	0.000319	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GBA—hematologic cancer	4.86e-06	0.000319	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—IDH1—hematologic cancer	4.84e-06	0.000317	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ABCC3—hematologic cancer	4.79e-06	0.000314	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTO1—hematologic cancer	4.79e-06	0.000314	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TXN—hematologic cancer	4.79e-06	0.000314	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—IDH2—hematologic cancer	4.77e-06	0.000313	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HMMR—hematologic cancer	4.77e-06	0.000313	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PRKCZ—hematologic cancer	4.73e-06	0.00031	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SPHK1—hematologic cancer	4.69e-06	0.000307	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CG—hematologic cancer	4.62e-06	0.000303	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PARP1—hematologic cancer	4.56e-06	0.000299	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—UGT1A1—hematologic cancer	4.5e-06	0.000295	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	4.5e-06	0.000295	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FBXW7—hematologic cancer	4.49e-06	0.000294	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ARNTL—hematologic cancer	4.49e-06	0.000294	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTAP—hematologic cancer	4.44e-06	0.000291	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HDAC2—hematologic cancer	4.4e-06	0.000289	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CXCR4—hematologic cancer	4.4e-06	0.000289	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CRABP1—hematologic cancer	4.38e-06	0.000287	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC22A1—hematologic cancer	4.38e-06	0.000287	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CA9—hematologic cancer	4.36e-06	0.000286	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ACP5—hematologic cancer	4.36e-06	0.000286	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOR2—hematologic cancer	4.31e-06	0.000282	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CBL—hematologic cancer	4.29e-06	0.000281	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALOX5—hematologic cancer	4.27e-06	0.00028	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL3—hematologic cancer	4.25e-06	0.000278	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CG—hematologic cancer	4.19e-06	0.000275	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTPN1—hematologic cancer	4.17e-06	0.000274	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NUP98—hematologic cancer	4.13e-06	0.000271	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PTPN11—hematologic cancer	4.12e-06	0.00027	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RASGRP1—hematologic cancer	4.11e-06	0.000269	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—IDH1—hematologic cancer	4.1e-06	0.000269	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HSP90AA1—hematologic cancer	4.09e-06	0.000268	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SYK—hematologic cancer	4.09e-06	0.000268	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CD—hematologic cancer	4.06e-06	0.000266	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ABCC3—hematologic cancer	4.06e-06	0.000266	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTO1—hematologic cancer	4.06e-06	0.000266	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TXN—hematologic cancer	4.06e-06	0.000266	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ADCY7—hematologic cancer	4.01e-06	0.000263	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOA3—hematologic cancer	4.01e-06	0.000263	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CREB1—hematologic cancer	3.99e-06	0.000262	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NUP214—hematologic cancer	3.99e-06	0.000261	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SPHK1—hematologic cancer	3.97e-06	0.00026	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—FHL2—hematologic cancer	3.96e-06	0.00026	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT1—hematologic cancer	3.95e-06	0.000259	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CCL2—hematologic cancer	3.91e-06	0.000256	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ABCG2—hematologic cancer	3.9e-06	0.000256	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MTR—hematologic cancer	3.9e-06	0.000256	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL6R—hematologic cancer	3.89e-06	0.000255	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—AGRN—hematologic cancer	3.89e-06	0.000255	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3R1—hematologic cancer	3.83e-06	0.000251	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ENO2—hematologic cancer	3.83e-06	0.000251	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—UGT1A1—hematologic cancer	3.82e-06	0.00025	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—JAK2—hematologic cancer	3.73e-06	0.000244	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.71e-06	0.000243	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—MAP2K1—hematologic cancer	3.71e-06	0.000243	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CRABP1—hematologic cancer	3.71e-06	0.000243	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC22A1—hematologic cancer	3.71e-06	0.000243	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GRB2—hematologic cancer	3.69e-06	0.000242	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CD—hematologic cancer	3.69e-06	0.000242	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDGFA—hematologic cancer	3.68e-06	0.000241	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—IDH2—hematologic cancer	3.68e-06	0.000241	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HMMR—hematologic cancer	3.68e-06	0.000241	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KITLG—hematologic cancer	3.63e-06	0.000238	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SDC1—hematologic cancer	3.63e-06	0.000238	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALOX5—hematologic cancer	3.62e-06	0.000237	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT5A—hematologic cancer	3.55e-06	0.000233	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CB—hematologic cancer	3.54e-06	0.000232	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN2B—hematologic cancer	3.52e-06	0.000231	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NUP98—hematologic cancer	3.5e-06	0.00023	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3R1—hematologic cancer	3.48e-06	0.000228	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.46e-06	0.000227	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CD86—hematologic cancer	3.4e-06	0.000223	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ADCY7—hematologic cancer	3.4e-06	0.000223	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOA3—hematologic cancer	3.4e-06	0.000223	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—JAK2—hematologic cancer	3.38e-06	0.000222	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NUP214—hematologic cancer	3.38e-06	0.000221	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ACP5—hematologic cancer	3.37e-06	0.000221	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CA9—hematologic cancer	3.37e-06	0.000221	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HES1—hematologic cancer	3.36e-06	0.00022	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.34e-06	0.000219	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NCOR1—hematologic cancer	3.34e-06	0.000219	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.32e-06	0.000218	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ABCG2—hematologic cancer	3.31e-06	0.000217	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTR—hematologic cancer	3.31e-06	0.000217	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGF1—hematologic cancer	3.3e-06	0.000216	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CSF2—hematologic cancer	3.3e-06	0.000216	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FOXO1—hematologic cancer	3.25e-06	0.000213	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—IL2—hematologic cancer	3.25e-06	0.000213	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDGFRB—hematologic cancer	3.25e-06	0.000213	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ENO2—hematologic cancer	3.24e-06	0.000213	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CB—hematologic cancer	3.21e-06	0.000211	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDGFRA—hematologic cancer	3.2e-06	0.000209	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JAK1—hematologic cancer	3.18e-06	0.000209	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PRKCG—hematologic cancer	3.18e-06	0.000209	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—IDH1—hematologic cancer	3.17e-06	0.000208	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTT1—hematologic cancer	3.15e-06	0.000206	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.13e-06	0.000205	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.13e-06	0.000205	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TXN—hematologic cancer	3.13e-06	0.000205	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.1e-06	0.000203	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NQO1—hematologic cancer	3.09e-06	0.000202	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CD44—hematologic cancer	3.09e-06	0.000202	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SDC1—hematologic cancer	3.08e-06	0.000202	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.06e-06	0.000201	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL2RA—hematologic cancer	2.97e-06	0.000195	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL2—hematologic cancer	2.95e-06	0.000193	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.94e-06	0.000193	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TERT—hematologic cancer	2.94e-06	0.000193	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.94e-06	0.000193	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYCS—hematologic cancer	2.92e-06	0.000191	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.9e-06	0.00019	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.9e-06	0.00019	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PDGFB—hematologic cancer	2.87e-06	0.000188	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.86e-06	0.000188	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.86e-06	0.000188	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TSC2—hematologic cancer	2.81e-06	0.000184	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.79e-06	0.000183	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.77e-06	0.000182	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NUP98—hematologic cancer	2.7e-06	0.000177	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGFR3—hematologic cancer	2.7e-06	0.000177	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK14—hematologic cancer	2.67e-06	0.000175	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.62e-06	0.000172	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.62e-06	0.000172	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ESR1—hematologic cancer	2.62e-06	0.000172	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CD44—hematologic cancer	2.61e-06	0.000171	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NQO1—hematologic cancer	2.61e-06	0.000171	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NUP214—hematologic cancer	2.61e-06	0.000171	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FN1—hematologic cancer	2.59e-06	0.00017	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.57e-06	0.000169	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.56e-06	0.000168	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—BAD—hematologic cancer	2.56e-06	0.000168	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	2.56e-06	0.000168	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.55e-06	0.000167	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTR—hematologic cancer	2.55e-06	0.000167	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	2.53e-06	0.000166	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ENO2—hematologic cancer	2.5e-06	0.000164	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CD80—hematologic cancer	2.48e-06	0.000163	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	2.48e-06	0.000162	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KIT—hematologic cancer	2.48e-06	0.000162	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	2.48e-06	0.000162	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYCS—hematologic cancer	2.47e-06	0.000162	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.46e-06	0.000161	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.44e-06	0.00016	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	2.43e-06	0.00016	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.43e-06	0.000159	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SDC1—hematologic cancer	2.37e-06	0.000156	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	2.37e-06	0.000156	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.37e-06	0.000155	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.37e-06	0.000155	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CREB1—hematologic cancer	2.36e-06	0.000155	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—BRAF—hematologic cancer	2.33e-06	0.000153	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCL2—hematologic cancer	2.31e-06	0.000151	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL6R—hematologic cancer	2.3e-06	0.000151	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	2.3e-06	0.000151	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.21e-06	0.000145	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	2.19e-06	0.000144	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.18e-06	0.000143	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	2.18e-06	0.000143	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.16e-06	0.000141	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	2.13e-06	0.00014	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.11e-06	0.000138	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.09e-06	0.000137	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGF2—hematologic cancer	2.09e-06	0.000137	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.06e-06	0.000135	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	2.06e-06	0.000135	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NQO1—hematologic cancer	2.02e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CD44—hematologic cancer	2.02e-06	0.000132	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOR1—hematologic cancer	2e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTM1—hematologic cancer	2e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JAK2—hematologic cancer	2e-06	0.000131	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.96e-06	0.000128	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MDM2—hematologic cancer	1.95e-06	0.000128	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYCS—hematologic cancer	1.91e-06	0.000125	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	1.9e-06	0.000124	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	1.9e-06	0.000124	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.9e-06	0.000124	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	1.81e-06	0.000119	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	1.78e-06	0.000117	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.77e-06	0.000116	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	1.76e-06	0.000116	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.76e-06	0.000115	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	1.75e-06	0.000114	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL2—hematologic cancer	1.74e-06	0.000114	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	1.73e-06	0.000114	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	1.7e-06	0.000111	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JUN—hematologic cancer	1.7e-06	0.000111	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.68e-06	0.00011	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	1.64e-06	0.000108	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	1.64e-06	0.000108	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.63e-06	0.000107	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	1.6e-06	0.000105	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	1.6e-06	0.000105	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.59e-06	0.000104	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.56e-06	0.000103	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.56e-06	0.000102	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.55e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.55e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.54e-06	0.000101	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ALB—hematologic cancer	1.52e-06	9.99e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.52e-06	9.97e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.49e-06	9.75e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.48e-06	9.71e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.47e-06	9.62e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.46e-06	9.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.46e-06	9.56e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.4e-06	9.19e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.38e-06	9.04e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.37e-06	8.96e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.36e-06	8.94e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.36e-06	8.91e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.35e-06	8.82e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.31e-06	8.57e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ALB—hematologic cancer	1.29e-06	8.46e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.26e-06	8.26e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.24e-06	8.1e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.16e-06	7.62e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.16e-06	7.59e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.15e-06	7.53e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.14e-06	7.47e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.12e-06	7.34e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—EP300—hematologic cancer	1.11e-06	7.27e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.07e-06	7.02e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.06e-06	6.98e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.02e-06	6.72e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.01e-06	6.62e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ALB—hematologic cancer	9.97e-07	6.53e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTEN—hematologic cancer	9.85e-07	6.46e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	9.53e-07	6.25e-05	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	9.45e-07	6.2e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—EP300—hematologic cancer	9.4e-07	6.16e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.8e-07	5.77e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.21e-07	5.38e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTEN—hematologic cancer	7.6e-07	4.98e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—EP300—hematologic cancer	7.25e-07	4.75e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.95e-07	4.56e-05	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—AKT1—hematologic cancer	6.7e-07	4.39e-05	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—AKT1—hematologic cancer	5.68e-07	3.72e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.36e-07	3.52e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—AKT1—hematologic cancer	4.38e-07	2.87e-05	CbGpPWpGaD
